atrial

Atrial Natriuretic Peptide (1-28), human, porcine, Biotin-labeled, is one of three mammalian natriuretic peptides (NPs) with endocrine effects on fluid homeostasis and blood pressure, holding promise for cardiovascular disease research.

Atrial natriuretic factor (1-28) from both human and porcine sources is a potent suppressor of pro-opiomelanocortin (POMC) mRNA, exerting only a modest inhibitory effect on βEP-LI release.

Atrial natriuretic peptide (3-28) (human) (ANP (3-28) (human)), a peptide hormone produced by the atrial myocardium, critically regulates blood pressure, fluid balance, and electrolyte homeostasis [1] [2].

Prepro-Atrial Natriuretic Factor (26-55) (human) is a polypeptide that increases cyclic GMP levels in the renal cortex and medulla, and enhances renal guanylate cyclase activity [1].

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA), is the primary circulating form of ANP in rats and significantly inhibits Ang II-stimulated secretion of endothelin-1.

Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate is an atrial natriuretic peptide (ANP) hormone secreted by atrial myocytes that is capable of acting as an natriuretic peptide receptor-A(NPR-A) agonist, used in the treatment of acute decompensated heart failure (ADHF). By binding to specific receptors on the surface of the kidney, blood vessel, and heart cells, Carperitide causes an increase in cyclic guanosine monophosphate (cGMP) levels and induces vasodilatation, diuresis, and sodium excretion, which in turn reduces the heart's workload.

Atrial Natriuretic Peptide (1-28), rat is the major circulating form of ANP in rats.

Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits antihypertensive activity by promoting sodium and urine excretion. It inhibits the release of adrenocorticotropic hormone (ACTH) and β-endorphin by suppressing pro-opiomelanocortin (POMC) expression. Additionally, it elevates cGMP levels in RMIC cells, with an IC50 of 1.2 nM.

A 71915, an atrial natricuretic factor receptor antagonist, blocks physiological effects of angiotensin.

AP 811, a selective antagonist of the atrial natriuretic peptide clearance receptor (APN-CR, NPR3) with a K i value of 0.48 nM, exhibits remarkable selectivity for NPR3 over NPR1 by more than 20,000-fold. Moreover, AP 811 effectively eliminates ANP-induced pump stimulation.

ANP (1-30), frog, a peptide fragment sourced from atrial natriuretic peptide of frog origin, exhibits natriuretic, diuretic, and vasorelaxant properties.

Prepro-ANF (56-92), human, a precursor to the human atrial natriuretic factor, activates guanylate cyclase by specifically enhancing particulate guanylate cyclase activity within the renal membrane and unit [1].

Vasonatrin Peptide (VNP) TFA, a chimeric compound derived from atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), exhibits venodilating properties reminiscent of CNP, natriuretic effects akin to ANP, as well as unique arterial vasodilating capabilities not characteristic of either parent peptide. Additionally, VNP TFA confers cardioprotection in diabetic ischemia-reperfusion injury by attenuating endoplasmic reticulum (ER) stress through the cGMP-PKG signaling cascade [1] [2] [3].

ATX-II, an Na+ channel modulator toxin derived from the sea anemone (Anemonia sulcata), causes delayed inactivation of the Na+ channels and has been linked to pulmonary vein arrhythmogenesis and atrial fibrillation [1] [2]. It exhibits interaction with halothane, caffeine, and ryanodine.

M65 is a PAC1 receptor-specific antagonist that inhibits the secretion of atrial natriuretic peptide (ANP) [1].

BNP (1-21), Pro (Human) is a 21-amino acid peptide and a form of B-Type Natriuretic Peptide (BNP), a cardiac natriuretic hormone that coexists with the homologous atrial natriuretic peptide in the heart's dual natriuretic peptide system. BNP plays a critical role in heart organogenesis and the transition to extrauterine life [1] [2] [3].

Auriculin B (ANP (126-150) (Rat)), a rat-derived atrial natriuretic peptide, demonstrates strong vasodilatory and diuretic properties [1].

Auriculin A, a synthetic atrial natriuretic factor (ANF), exhibits hemodynamic properties by antagonizing renal vasoconstriction in dogs and affects arterial baroreflex regulation of heart rate, systemic blood pressure, and constant flow-perfused hind limb perfusion pressure in rabbits [1] [2].

ATX-II TFA, a specific Na+ channel modulator toxin, is derived from the venom of the sea anemone (Anemonia sulcata). This compound impedes the inactivation of Na+ channels and has been associated with arrhythmogenesis in the pulmonary vein and atrial fibrillation [1] [2]. It interacts with halothane, caffeine, and ryanodine in this modulation.

Atriopeptin III (rat) (ANP 127-150), a 24-amino acid atrial peptide, functions as a powerful vasodilator and natriuretic diuretic agent, enhancing renal functions and reducing blood pressure in a rat model with ureter-obstructed kidneys. It is utilized in research concerning chronic renal failure [1].

AP 811 acetate is a selective antagonist of the atrial natriuretic peptide clearance receptor (ANP-CR, NPR3), with a high affinity (K_i = 0.48 nM) and over 20,000-fold selectivity for NPR3 compared to NPR1, effectively inhibiting ANP-induced pump stimulation [1] [2].

Carperitide acetate (Atrial Natriuretic Peptide (ANP) (1-28), human, porcine Acetate), a 28-amino acid hormone, is naturally produced and released by the human heart upon cardiac injury or mechanical stretch. This compound effectively inhibits the secretion of endothelin-1 in a dose-dependent manner.

A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells.

Vasonatrin peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP) with potent venodilating and natriuretic activity.